Onkologie. 2023:17(5):312-315 | DOI: 10.36290/xon.2023.058

Risks of hemato-oncological diseases in Noonan syndrome

Terézia Tureková1, 2, Danica Zapletalová1, 2, Hana Bernatíková1, 2, Martin Baláž1, 2, Klára Drábová1, 2
1 Klinika dětské onkologie, Fakultní nemocnice, Brno
2 Lékařská fakulta, Masarykova univerzita, Brno

Noonan syndrome is a common hereditary condition with a heterogeneous genetic background and great variability in clinical manifestations. In addition to various birth defects and abnormalities, the affected patients have also an increased risk of developing a malignant disease in childhood. In the following case reports, we present two typical hemato-oncological diagnoses associated with Noonan syndrome - transient myeloproliferative disorder and acute lymphoblastic leukemia. Differences in the case history, diagnostic process and the course of treatment led us to search for the genetic basis of the difficulties with the subsequent confirmation of Noonan's syndrome.

Keywords: Noonan syndrome, juvenile myelomonocytic leukemia, acute lymphoblastic leukemia, transient myeloproliferative disorder.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tureková T, Zapletalová D, Bernatíková H, Baláž M, Drábová K. Risks of hemato-oncological diseases in Noonan syndrome. Onkologie. 2023;17(5):312-315. doi: 10.36290/xon.2023.058.
Download citation

References

  1. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet. 1985;21(3):493-506. Go to original source... Go to PubMed...
  2. Tartaglia M, Cordeddu V, Chang H, et al. Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. Am J Hum Genet. 2004;75(3):492-497. Go to original source... Go to PubMed...
  3. Niemeyer CM. RAS diseases in children. Haematologica. 2014;99(11):1653-1662. Go to original source... Go to PubMed...
  4. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746-759. Go to original source... Go to PubMed...
  5. Kratz CP, Franke L, Peters H, et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015;112(8):1392-1397. Go to original source... Go to PubMed...
  6. Cavé H, Caye A, Strullu M, et al. Acute lymphoblastic leukemia in the context of RASopathies. Eur J Med Genet. 2016;59(3):173-178. Go to original source... Go to PubMed...
  7. Wintering A, Dvorak CC, Stieglitz E, et al. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. Blood Adv. 2021;5(22):4783-4793. Go to original source... Go to PubMed...
  8. Calcagni G, Limongelli G, D'Ambrosio A, et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int J Cardiol. 2017;245:92-98. Go to original source... Go to PubMed...
  9. Prendiville TW, Gauvreau K, Tworog-Dube E, AE, et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child. 2014;99(7):629-634. Go to original source... Go to PubMed...
  10. Pierpont EI. Neuropsychological Functioning in Individuals with Noonan Syndrome: a Systematic Literature Review with Educational and Treatment Recommendations. J Pediatr Neuropsychol. 2016;2(1):14-33. Go to original source...
  11. Artoni A, Selicorni A, Passamonti SM, et al. Hemostatic abnormalities in Noonan syndrome. Pediatrics. 2014;133(5):e1299-1304. Go to original source... Go to PubMed...
  12. Villani A, Greer MLC, Kalish JM, et al. Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(12):e83-90. Go to original source... Go to PubMed...
  13. Meynier S, Rieux-Laucat F. After 95 years, it's time to eRASe JMML. Blood Rev. 2020;43:100652. Go to original source... Go to PubMed...
  14. Mayerhofer C, Niemeyer CM, Flotho C. Current Treatment of Juvenile Myelomonocytic Leukemia. J Clin Med. 2021;10(14):3084. Go to original source... Go to PubMed...
  15. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. Go to original source... Go to PubMed...
  16. Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. Journal of Clinical Oncology. 2023;41(19):3499-3511. Go to original source... Go to PubMed...
  17. Bajčiová V. Dědičné nádorové syndromy v dětské onkologii. Praha: Current Media; 2020.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.